Home
ATOS
ATOS News

Latest Atossa Therapeutics Inc. (ATOS) News on August 23, 2025

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

PR Newswire

3 days ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

PR Newswire

3 months ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

ACCESS Newswire

3 months ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Zacks

3 months ago

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

PR Newswire

3 months ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

PR Newswire

3 months ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

ACCESS Newswire

4 months ago

Atossa Therapeutics and Ainos Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

GlobeNewswire

4 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

GlobeNewswire

4 months ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

GlobeNewswire

4 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

PR Newswire

4 months ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy

Zacks

5 months ago

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Simply Wall St.

5 months ago

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire

5 months ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

5 months ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

GlobeNewswire

5 months ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

GlobeNewswire

7 months ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

GlobeNewswire

7 months ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

GlobeNewswire

7 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

GlobeNewswire

8 months ago

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Zacks

8 months ago

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Atossa Therapeutics to present poster on Z-endoxifen at SABCS

TipRanks

8 months ago

Atossa Therapeutics to present poster on Z-endoxifen at SABCS

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

8 months ago

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

GlobeNewswire

8 months ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

8 months ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

GlobeNewswire

8 months ago

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

GlobeNewswire

9 months ago

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

9 months ago

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

Zacks

9 months ago

Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

9 months ago

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

GlobeNewswire

10 months ago

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

GlobeNewswire

10 months ago

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

GlobeNewswire

10 months ago

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Zacks

10 months ago

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

GlobeNewswire

10 months ago

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire

10 months ago

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

GlobeNewswire

a year ago

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Zacks

a year ago

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

GlobeNewswire

a year ago

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?

Zacks

a year ago

Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

a year ago

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice

Zacks

a year ago

Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

GlobeNewswire

a year ago

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

GlobeNewswire

a year ago

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

GlobeNewswire

a year ago

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

GlobeNewswire

a year ago

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Zacks

a year ago

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

GlobeNewswire

a year ago

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

GlobeNewswire

a year ago

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Are Medical Stocks Lagging Alvotech (ALVO) This Year?

Zacks

a year ago

Are Medical Stocks Lagging Alvotech (ALVO) This Year?

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

GlobeNewswire

a year ago

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Sidoti Events, LLC's Virtual June Small-Cap Conference

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual June Small-Cap Conference

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Simply Wall St.

a year ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

Simply Wall St.

a year ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Motley Fool

a year ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Simply Wall St.

a year ago

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Simply Wall St.

a year ago

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Seoul resumes loudspeaker propaganda against North

AFP

a year ago

Seoul resumes loudspeaker propaganda against North

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Zacks

a year ago

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Atossa to Present at the Sidoti Small-Cap Investor Conference

GlobeNewswire

a year ago

Atossa to Present at the Sidoti Small-Cap Investor Conference

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

GlobeNewswire

a year ago

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?

Zacks

a year ago

Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

GlobeNewswire

a year ago

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

GlobeNewswire

a year ago

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

ACCESSWIRE

a year ago

Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

GlobeNewswire

a year ago

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

GlobeNewswire

a year ago

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

GlobeNewswire

a year ago

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

GlobeNewswire

a year ago

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

GlobeNewswire

a year ago

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

GlobeNewswire

a year ago

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

GlobeNewswire

a year ago

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire

a year ago

Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Simply Wall St.

a year ago

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

GlobeNewswire

2 years ago

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

GlobeNewswire

2 years ago

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

Associated Press Finance

2 years ago

Codorus Valley: Q4 Earnings Snapshot

Codorus Valley Bancorp, Inc. Reports Fourth Quarter 2023 Results and Record Earnings for the Year

GlobeNewswire

2 years ago

Codorus Valley Bancorp, Inc. Reports Fourth Quarter 2023 Results and Record Earnings for the Year

Associated Press Finance

2 years ago

Ohio Valley Banc: Q4 Earnings Snapshot

Business Wire

2 years ago

MtronPTI to Present at the Microcap Conference in Atlantic City

Ohio Valley Banc Corp. Reports 4th Quarter and Fiscal Year Earnings

PR Newswire

2 years ago

Ohio Valley Banc Corp. Reports 4th Quarter and Fiscal Year Earnings

IBN Announces Latest Episode of The Stock2Me Podcast featuring Dr. Alan Baratz, CEO of D-Wave Quantum Inc.

GlobeNewswire

2 years ago

IBN Announces Latest Episode of The Stock2Me Podcast featuring Dr. Alan Baratz, CEO of D-Wave Quantum Inc.

NOVONIX to Host Fourth Quarter 2023 Operations Update

GlobeNewswire

2 years ago

NOVONIX to Host Fourth Quarter 2023 Operations Update

GlobeNewswire

2 years ago

National Bankshares, Inc. Announces Agreement to Acquire Frontier Community Bank

Q3 Earnings Outperformers: Shake Shack (NYSE:SHAK) And The Rest Of The Modern Fast Food Stocks

StockStory

2 years ago

Q3 Earnings Outperformers: Shake Shack (NYSE:SHAK) And The Rest Of The Modern Fast Food Stocks

Newsfile

2 years ago

Heritage Global, Inc. to Present at The Microcap Conference on Wednesday, January 31 and Thursday, February 1, 2024

DISCO Announces C-Suite Elevations For Key Customer and People-Focused Roles

Business Wire

2 years ago

DISCO Announces C-Suite Elevations For Key Customer and People-Focused Roles

Seven Hills Realty Trust Fourth Quarter 2023 Conference Call Scheduled for Wednesday, February 21st

Business Wire

2 years ago

Seven Hills Realty Trust Fourth Quarter 2023 Conference Call Scheduled for Wednesday, February 21st

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

GlobeNewswire

2 years ago

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

GlobeNewswire

2 years ago

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

Atossa Therapeutics, Inc. (NASDAQ:ATOS): Is Breakeven Near?

Simply Wall St.

2 years ago

Atossa Therapeutics, Inc. (NASDAQ:ATOS): Is Breakeven Near?

Q3 Modern Fast Food Earnings: Wingstop (NASDAQ:WING) Earns Top Marks

StockStory

2 years ago

Q3 Modern Fast Food Earnings: Wingstop (NASDAQ:WING) Earns Top Marks

Ohio Valley Banc Corp. (NASDAQ:OVBC) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Simply Wall St.

2 years ago

Ohio Valley Banc Corp. (NASDAQ:OVBC) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Spotting Winners: Noodles (NASDAQ:NDLS) And Modern Fast Food Stocks In Q3

StockStory

2 years ago

Spotting Winners: Noodles (NASDAQ:NDLS) And Modern Fast Food Stocks In Q3

Share on Social Networks: